Versartis Raises $11M

Redwood City-based Versartis, a new joint venture between Amunix Inc. and Index Ventures, said today that it has raised $11M in a Series A financing round. The round came from index Ventures. According to the company, it was created to exploit the clinical potential of novel drugs using Amunix's recombinant PEGylation (rPEG) technology. The technology is being targeted at creation of therapeutic proteins, in the area of metabolic disease and endocrinology. More information »